EARLY BLOOD CELL COUNT TEST (BCT) FOR SURVIVAL PREDICTION FOR NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH ATEZOLIZUMAB: INTEGRATED ANALYSIS OF 4 MULTICENTER CLINICAL TRIALS

Zhou JG, Wong AHH, Wang H, Jin SH, Tan F, Chen YZ, He SS, Shen G, Frey B, Fietkau R, Hecht M, Shen B, Ma H, Gaipl U (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: A355-A355

Conference Proceedings Title: JOURNAL FOR IMMUNOTHERAPY OF CANCER

DOI: 10.1136/jitc-2021-SITC2021.329

Abstract

Immune checkpoint inhibitor (ICI) therapy is a major breakthrough for non-small cell lung cancer (NSCLC) treatment given its high efficacy and tolerable toxicity. Although pre-treatment PD-L1 expression levels and tumor mutation burden (TMB) may serve as prognostic biomarkers for patient stratification, effective predictive biomarkers are lacking. Blood cell count test (BCT) is a routine, regular blood test conducted before and during treatment to provide a direct overview of the immune landscape based on the counts of various types of immune cells (ICs). For instance, previous studies showed that neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) both indicate poor treatment outcomes of ICI therapy of NSCLC patients.

Authors with CRIS profile

Involved external institutions

Zunyi Medical University China (CN) University at Buffalo. State University of New York United States (USA) (US) US National Institutes of Health (NIH) United States (USA) (US) Nanjing Medical University / 南京医科大学 China (CN) University of Macau (UM) / Universidade de Macau / 澳門大學 Macao (MO)

How to cite

APA:

Zhou, J.-G., Wong, A.H.-H., Wang, H., Jin, S.-H., Tan, F., Chen, Y.-Z.,... Gaipl, U. (2021). EARLY BLOOD CELL COUNT TEST (BCT) FOR SURVIVAL PREDICTION FOR NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH ATEZOLIZUMAB: INTEGRATED ANALYSIS OF 4 MULTICENTER CLINICAL TRIALS. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (pp. A355-A355). LONDON: BMJ PUBLISHING GROUP.

MLA:

Zhou, Jian-Guo, et al. "EARLY BLOOD CELL COUNT TEST (BCT) FOR SURVIVAL PREDICTION FOR NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH ATEZOLIZUMAB: INTEGRATED ANALYSIS OF 4 MULTICENTER CLINICAL TRIALS." Proceedings of the JOURNAL FOR IMMUNOTHERAPY OF CANCER LONDON: BMJ PUBLISHING GROUP, 2021. A355-A355.

BibTeX: Download